

FORM 4

UNITED STATES SECURITIES AND EXCHANGE
COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Estimated average
 burden hours
 per response 0.5

☐ Check this box if no longer
 subject to Section 16. Form 4 or
 Form 5 obligations may
 continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
 or Section 30(h) of the Investment Company Act of 1940

☐ Check this box to indicate that a
 transaction was made pursuant
 to a contract, instruction or
 written plan that is intended to
 satisfy the affirmative defense
 conditions of Rule 10b5-1(c).
 See Instruction 10.

1. Name and Address of Reporting Person* Manieu Alexandre Weinstein <hr/> (Last) (First) (Middle) APT 8002, BURGENSTOCK HOTELS & RESORT, BURGENSTOCK 30 <hr/> (Street) OBBURGEN V8 6363 <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Pluri Inc. [PLUR] <hr/> 3. Date of Earliest Transaction (Month/Day/Year) 12/04/2025 <hr/> 4. If Amendment, Date of Original Filed (Month/Day/Year)	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below) <hr/> 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person
--	--	---

Table I – Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/04/2025 ⁽¹⁾		A		519 ⁽¹⁾	A	\$0	10,769	D	
Common Stock								1,933,415	I	Shares indirectly held through Chutzpah Holdings Limited ⁽²⁾
Common Stock								452,702	I	Shares indirectly held through Plantae Bioscience Ltd. ⁽³⁾

Table II – Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					
									Amount or Number of Shares				

1. Name and Address of Reporting Person* Manieu Alexandre Weinstein	10% Owner Director
(Last) (First) (Middle) APT 8002, BURGENSTOCK HOTELS & RESORT, BURGENSTOCK 30	
(Street) OBBURGEN V8 6363	
(City) (State) (Zip)	
1. Name and Address of Reporting Person* Chutzpah Holdings Ltd	10% Owner
(Last) (First) (Middle) 4TH FLOOR, LIBERATION HOUSE CASTLE STREET	
(Street) ST. HELIER Y9 JE1 4HH	
(City) (State) (Zip)	

Explanation of Responses:

1. The restricted stock units ("RSUs") were approved for grant by the Board of Directors on December 4, 2025, under the Company's 2019 Equity Compensation Plan. The RSUs vest equally on a monthly basis over three months following the date of grant.
2. This statement is jointly filed by and on behalf of each of Chutzpah Holdings Limited ("Chutzpah") and Mr. Weinstein. Mr. Weinstein indirectly owns 100% of Chutzpah and may be deemed to beneficially own securities owned by Chutzpah.
3. Mr. Weinstein indirectly owns 77% of Plantae Bioscience Ltd. ("Plantae") and may be deemed to beneficially own securities owned by Plantae. Neither the filing of this statement nor anything herein shall be deemed an admission that Mr. Weinstein is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any securities owned by Plantae. Mr. Weinstein disclaims beneficial ownership of such securities covered by this statement, except to the extent of his pecuniary interest in such securities. Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.

Remarks:

Exhibit Index: Exhibit 99.1 - Joint Filer Information (incorporated by reference to Exhibit 99.1 for Form 3 filed with the Securities and Exchange Commission on February 18, 2025). Exhibit 99.2 - Joint Filing Agreement (incorporated by reference to Exhibit 99.2 for Form 3 filed with the Securities and Exchange Commission on February 18, 2025). Each reporting person states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any securities covered by this statement. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities. Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.

<u>/s/ Alexandre Weinstein Manieu</u>	<u>12/08/2025</u>
** Signature of Reporting Person	Date
<u>/s/ Ana Ventura Authorized Officer For Beaumont (Directors) Limited Sole Corporate Director</u>	<u>12/08/2025</u>
** Signature of Reporting Person	Date
<u>/s/ Karen Oliver Authorized Officer For Beaumont (Directors) Limited Sole Corporate Director</u>	<u>12/08/2025</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.